scholarly article | Q13442814 |
P2093 | author name string | Vinod Labhasetwar | |
Wenxue Ma | |||
Jayanth Panyam | |||
Blanka Sharma | |||
Sanja Dimitrijevic | |||
Isaac Morris Adjei | |||
P2860 | cites work | Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells | Q70545069 |
TP53 gene mutations in prostate cancer progression | Q84510020 | ||
Surfing the p53 network | Q28032484 | ||
Live or let die: the cell's response to p53 | Q29547663 | ||
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents | Q29615031 | ||
Transcriptional control of human p53-regulated genes | Q29617650 | ||
Cancer stem cells: models and concepts | Q29620611 | ||
Non-viral gene delivery using nanoparticles. | Q30381073 | ||
Germline mutations and polymorphisms in the origins of cancers in women | Q33606675 | ||
Optical Imaging and Magnetic Field Targeting of Magnetic Nanoparticles in Tumors | Q34164158 | ||
Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy | Q34328569 | ||
Awakening guardian angels: drugging the p53 pathway | Q35014385 | ||
Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. | Q36710840 | ||
Recent advances in p53 research: an interdisciplinary perspective. | Q37273304 | ||
Viral vectors for gene transfer: current status of gene therapeutics | Q37706296 | ||
Receptor-targeted nanocarriers for therapeutic delivery to cancer | Q37804383 | ||
Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection | Q39425663 | ||
Cancer progression and p53. | Q40369102 | ||
Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells | Q40404364 | ||
Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery | Q40713744 | ||
Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity | Q41133661 | ||
Systemic gene delivery expands the repertoire of effective antiangiogenic agents | Q41649129 | ||
Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene | Q43215992 | ||
Regulation of cancer stem cells by p53. | Q43249111 | ||
Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel | Q43287891 | ||
p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy | Q43950150 | ||
Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells | Q44361209 | ||
Critical determinants in PLGA/PLA nanoparticle-mediated gene expression | Q44403133 | ||
A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach | Q45861413 | ||
Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer | Q45874850 | ||
Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer | Q45887756 | ||
Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia | Q47990319 | ||
The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. | Q53370119 | ||
A DNA controlled-release coating for gene transfer: transfection in skeletal and cardiac muscle. | Q53942787 | ||
P433 | issue | 1 | |
P921 | main subject | nanoparticle | Q61231 |
gene therapy | Q213901 | ||
P304 | page(s) | 43-52 | |
P577 | publication date | 2011-02-01 | |
P1433 | published in | Drug delivery and translational research | Q27723621 |
P1476 | title | Nanoparticle-mediated p53 gene therapy for tumor inhibition | |
P478 | volume | 1 |
Q37298541 | Applications of nanoparticles in the detection and treatment of kidney diseases |
Q38819542 | Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy: An analytical technique to understand therapeutic responses at the molecular level. |
Q91610685 | Gene Therapy Today and Tomorrow |
Q37445335 | Heterogeneity in nanoparticles influences biodistribution and targeting |
Q36105141 | Inhibition of tumor angiogenesis and growth by nanoparticle-mediated p53 gene therapy in mice |
Q88432409 | Nanoparticle Properties for Delivery to Cartilage: The Implications of Disease State, Synovial Fluid, and Off-Target Uptake |
Q64981473 | Nonviral Gene Therapy for Cancer: A Review. |
Q45864098 | PTEN and TRAIL genes loaded zein nanoparticles as potential therapy for hepatocellular carcinoma |
Q36759358 | Poly(β-amino ester) nanoparticle delivery of TP53 has activity against small cell lung cancer in vitro and in vivo |
Q36893395 | Selective biophysical interactions of surface modified nanoparticles with cancer cell lipids improve tumor targeting and gene therapy |
Q57492228 | Targeted nonviral gene therapy in prostate cancer |